Exiting Covid-19 brings ResMed 20% growth
Sleep apnoea treatment company ResMed had a bumper first quarter of FY22 announcing quarterly revenue up 20 per cent on the previous corresponding quarter and operating profit up 21 per cent. The company announced revenue for the quarter of US$904 million and net income of US$203.6 million. ResMed, founded in and with major operations in…